Ibrutinib Capsules And Tablets Suppliers & Bulk Manufacturers
Available Forms: Capsules and tablets
Available Strengths: Capsule:140 mg, 70 mg; Tablet: 140 mg
Reference Brands: Imbruvica®(US & EU)
Category: Oncology Cancer Care
Ibrutinib Capsules and tablets is available in Capsules and tablets and strengths such as Capsule:140 mg, 70 mg; Tablet: 140 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ibrutinib Capsules and tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Ibrutinib Capsules and tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used in oncology and hematology to treat B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. By blocking Bruton’s tyrosine kinase (BTK), Ibrutinib disrupts B-cell signaling, preventing cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved for use in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a key product for B2B pharmaceutical transactions in the oncology and hematology sectors.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
